Novonesis Stock - Thursday chart snapshot and recent trading range

Novonesis stock trades quietly this Thursday, with investors watching the medium-term chart picture and recent range after the Novozymes-Christan Hansen merger that created the enzyme specialist.

Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 20:08 CET. Details in the imprint.

Novonesis (DK0060336014) remains a relatively new name on the market after the combination of Novozymes and Chr. Hansen, and the stock is currently trading in a calm range on Nasdaq Copenhagen. With no fresh corporate news today, the focus shifts to Thursday’s technical picture and recent trading levels, supported by official exchange data.

What the chart shows today

On Thursday, Novonesis shares trade on Nasdaq Copenhagen with modest volumes and within the range established over recent weeks, according to the latest exchange data. The stock continues to consolidate after the early-year listing under the new name that followed the merger of Novozymes and Chr. Hansen.

Short-term traders are watching how the price behaves around recent support and resistance zones rather than reacting to fresh headlines, as there is no new regulatory filing or major corporate announcement published on the company’s investor-relations page today. Against this backdrop, the intraday chart development is largely driven by broader sector sentiment and general market risk appetite.

Thursday focus on technicals

From a medium-term perspective, Novonesis stock remains tied to the broader European chemicals and ingredients sector, which itself has seen a mixed performance this week on the back of shifting interest-rate expectations and commodity-price moves. For Novonesis, the key technical focus is whether the shares can build a stable base after the merger integration phase and establish a recognizable trading range that investors can anchor to over the coming months.

For retail investors, volatility has been moderate compared with some more cyclical peers, reflecting the defensive nature often attributed to enzyme and biosolutions providers. Ultimately, Thursday’s technical snapshot is one piece in a larger picture that includes fundamental trends such as margin development, synergy realization from the merger and the company’s longer-term growth targets.

How the company makes money

Novonesis generates the bulk of its revenue by developing and producing industrial enzymes, microbial solutions and specialty ingredients that customers use in food and beverages, household care, bioenergy, agriculture and a range of industrial applications. The business model is built around close customer partnerships, high-value formulations and innovation in biosolutions that enable clients to improve efficiency, reduce environmental footprints and differentiate their products.

Where the stock trades today

The shares of Novonesis (DK0060336014) trade on Nasdaq Copenhagen at DKK 410.20 as of 06/18/2026, 16:30 CET.

Key facts on Novonesis stock

• Company: Novonesis A/S
• ISIN: DK0060336014
• WKN: A3EWQ9
• Ticker: NOVO
• Venue: Nasdaq Copenhagen
• Price (as of 06/18/2026, 16:30 CET): 410.20 DKK
• Market cap: 116,500,000,000 DKK (as of 06/18/2026)
• Sector / Industry: Materials - Specialty Chemicals / Biosolutions
• Index membership: OMX Copenhagen 25
• Next earnings date: 08/14/2026

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.